TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05879887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPHOLDS (Utilizing Palliative Care for Heart Failure Optimized using Lay Navigators to Decrease Suffering)
Description: UPHOLDS is a multicomponent, lay palliative care coach-led supportive care intervention designed to improve quality of life in individuals with advanced heart failure. In a series of weekly, one-on-one, 15-20 minute sessions, participants receive psychoeducation on palliative care principles (problem solving, self-care, symptom management, and advanced care planning), financial coaching (orientation to normalizing financial distress, introducing healthcare-related financial terms, exploring financial needs and steps to discussing finances in care decisions, and identifying financial resources in the health system and community), a one-time specialty palliative care outpatient clinic visit, as well as monthly follow-up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPHOLDS (Utilizing Palliative Care for Heart Failure Optimized using Lay Navigators to Decrease Suffering)
Description: UPHOLDS is a multicomponent, lay palliative care coach-led supportive care intervention designed to improve quality of life in individuals with advanced heart failure. In a series of weekly, one-on-one, 15-20 minute sessions, participants receive psychoeducation on palliative care principles (problem solving, self-care, symptom management, and advanced care planning), financial coaching (orientation to normalizing financial distress, introducing healthcare-related financial terms, exploring financial needs and steps to discussing finances in care decisions, and identifying financial resources in the health system and community), a one-time specialty palliative care outpatient clinic visit, as well as monthly follow-up.
Study: NCT04808323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohort B: Dose Escalation Radiation
Description: Cohort B will receive 18 Gy boost for a total of 68 Gy over 34 total fractions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohort C: Dose Escalation Radiation
Description: Cohort C will receive 22 Gy boost for a total of 72 Gy over 36 total fractions.
Study: NCT05576987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Students selected for the experimental group will be trained by the researcher for school accidents prepared in line with the components of the Health Belief Model.The training program will be planned as 30 minutes per week for 4 weeks. Before the training and at the end of the training (at the end of the 4th week), the students will be applied personal information form and a behavior scale for safety precautions in school accidents.
Study: NCT04808323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)
Study: NCT05987683

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Thread-Embedding Acupuncture, Sham Thread-Embedding Acupuncture
Description: Thread-Embedding Acupuncture: using a 29-gauge TEA needle with a 50-mm PDO (polydioxanone) thread Sham Thread-Embedding Acupuncture: using a 29-gauge TEA needle but thread-removed, just needle alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thread-Embedding Acupuncture, Sham Thread-Embedding Acupuncture
Description: Thread-Embedding Acupuncture: using a 29-gauge TEA needle with a 50-mm PDO (polydioxanone) thread Sham Thread-Embedding Acupuncture: using a 29-gauge TEA needle but thread-removed, just needle alone
Study: NCT05278000

Intervention type: OTHER
Intervention: Presence of scarcity mindset
Description: This observational study will examine whether~1. Individuals exhibiting a scarcity mindset have lower adherence to asthma controller medication~2. Individuals with higher rates of future discounting have lower adherence to controller medication~3. Individuals with unmet social needs are more likely to experience scarcity and have higher rates of future discounting, and whether these relationships mediate adherence to asthma controller medication
Study: NCT05789043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab+apatinib+TMZ
Description: camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg/m2，day1-5/28

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: camrelizumab+apatinib
Description: camrelizumab 200mg，q2w+apatinib 250mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: camrelizumab
Description: camrelizumab 200mg，q2w
Study: NCT06570863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotics(doxycycline)
Description: doxycycline 100 mg 2 stat the first day followed by od for 14 days
Study: NCT05036499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: Providing corrective normative feedback on alcohol use, psychoeducation on the interplay between pain and alcohol use, and providing exercises to target pain-related anxiety
Study: NCT06365177

Intervention type: OTHER
Group type: OTHER
Intervention: Physical consultation
Description: The subject enters a room where the therapist is present. A chair is placed against a wall in the same room.~Once again, the therapist suggests repeating the test. During the test, the therapist sits opposite the patient, at the same distance as the computer used during the teleconsultation.

Intervention type: OTHER
Group type: OTHER
Intervention: Physical consultation
Description: The subject enters a room where the therapist is present. A chair is placed against a wall in the same room.~Once again, the therapist suggests repeating the test. During the test, the therapist sits opposite the patient, at the same distance as the computer used during the teleconsultation.

Intervention type: OTHER
Group type: OTHER
Intervention: Teleconsultation
Description: Prior to the test, the investigator should carry out a mock test with a volunteer from the facility, for example, to ensure wifi, sound and image functionality.~The patient enters a room where a computer equipped with a webcam is set up on a desk. The teleconsultation has already started when the patient enters the room. No recordings are made.~A chair is placed at a distance from the desk, with the backrest against a wall. The chair faces the computer. The desk or table where the computer is located is about 3 meters from the participant, ensuring that the webcam can frame the patient's entire body during the test.~With the consultation already underway, the investigator can direct the patient to sit in the chair against the wall. The investigator will make sure that the patient hears the instructions given.~Once the patient is seated on the chair, the therapist explains the test procedure and shows it once to make sure the subject understands it.

Intervention type: OTHER
Group type: OTHER
Intervention: Teleconsultation
Description: Prior to the test, the investigator should carry out a mock test with a volunteer from the facility, for example, to ensure wifi, sound and image functionality.~The patient enters a room where a computer equipped with a webcam is set up on a desk. The teleconsultation has already started when the patient enters the room. No recordings are made.~A chair is placed at a distance from the desk, with the backrest against a wall. The chair faces the computer. The desk or table where the computer is located is about 3 meters from the participant, ensuring that the webcam can frame the patient's entire body during the test.~With the consultation already underway, the investigator can direct the patient to sit in the chair against the wall. The investigator will make sure that the patient hears the instructions given.~Once the patient is seated on the chair, the therapist explains the test procedure and shows it once to make sure the subject understands it.
Study: NCT05388864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three-Tier Model
Description: Families in the intervention will be counseled by a pediatric provider about ACEs, resilience, stress management, and healthy relationships. Families will also be referred to community health workers and parenting educators.
Study: NCT06570863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotic powder of Lactobacillus Reuteri. After mechanical debridement patient will be prescribed with Lactobacillus rhamnosus SP1 \[(2x107colony forming units (CFU)/ day)\] (Macrofood S.A., Santiago de Chile, Chile) for 1 month. The dose would be one sachet taken orally daily. The sachets presented to the patients would be identical. Individuals will be instructed to dissolve 1 sachet in water (150 mL) and ingest it once a day after brushing their teeth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metronidazole gel 25%
Description: After mechanical debridement, 25% of metronidazole gel was administered into the periodontal pockets. The gel was applied with a parojet syringe provided with a blunt cannula
Study: NCT04618198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate anti-TB therapy
Description: Study participants will receive immediate empiric anti-TB therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate anti-TB therapy
Description: Study participants will receive immediate empiric anti-TB therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sepsis-specific dose anti-TB therapy
Description: Study participants will receive conventional WHO weight-based dose anti-TB therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sepsis-specific dose anti-TB therapy
Description: Study participants will receive conventional WHO weight-based dose anti-TB therapy
Study: NCT06253000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoablation
Description: Cryoablation of the mouths of the pulmonary veins and the posterior wall of the left atrium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation of pulmonary veins according to the box isolation type using a non-fluoroscopic navigation system.
Study: NCT06016855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Debulking
Description: Undergo surgical debulking

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given by IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Computed Tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo Magnetic Resonance Imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 Dotatate
Description: Given by IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo Positron Emission Tomography
Study: NCT05258266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: Q.D., oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: Q.D., oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: Q.D., oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: Q.D., oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: Q.D., oral dosing
Study: NCT04813068

Intervention type: OTHER
Intervention: Semi-structured interview
Description: Semi-structured interview to identify attitudes to re-irradiation in lung cancer
Study: NCT05970510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg
Description: orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg
Description: orally once a day

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: orally once a day
Study: NCT05001009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low patient engagement
Description: Patients will be sent information about goals of care conversations, including the PREPARE website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low patient engagement
Description: Patients will be sent information about goals of care conversations, including the PREPARE website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low patient engagement
Description: Patients will be sent information about goals of care conversations, including the PREPARE website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High patient engagement
Description: Patients will be sent information about goals of care conversations, including the PREPARE website. Follow-up phone calls to discuss goals of care conversations and the PREPARE website will be made.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High patient engagement
Description: Patients will be sent information about goals of care conversations, including the PREPARE website. Follow-up phone calls to discuss goals of care conversations and the PREPARE website will be made.
Study: NCT04969081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: referral to work focused program
Description: referral to Incentive Therapy or to Other Therapeutic and Supported Employment Services

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: usual treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment as usual
Description: usual treatment
Study: NCT06097559

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial fluid and biopsy collection
Description: The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration) in a HRT cycle, according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET.

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial fluid and biopsy collection
Description: The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration), according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET. In case of a non-receptive endometrium result, a second EB sample must be collected when indicated by the ERA report. Fluid sample collection will not be repeated in these cases.
Study: NCT06525623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendation: No Further Resuscitation
Description: Treatment teams are encouraged not to administer any additional fluids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendation: Resuscitation with Crystalloid
Description: Treatment teams are encouraged to administer crystalloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendation: Resuscitation with Colloid
Description: Treatment teams are encouraged to administer colloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Recommendation: Standard of Care IV Albumin
Description: Treatment teams are encouraged to administer 1 g/kg/d IV albumin (maximum 100 g/day) over 2 days
Study: NCT05314517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namilumab
Description: Namilumab administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously to match namilumab dosing
Study: NCT06561711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium competitive acid blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Potassium competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline,Metronidazole
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline,Metronidazole
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline,Metronidazole
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline,Metronidazole
Description: Antibiotics for H. pylori eradication
Study: NCT06245083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrroloquinoline quinone (PQQ)
Description: Oral supplement taken daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with soybean oil
Description: Oral supplement taken daily
Study: NCT06216743

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI and CT
Description: Patients will undergo an additional MRI, cineMRI and CineCT cscan.
Study: NCT05769478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine
Description: a single dose of amifampridine (20mg) will be orally administered
Study: NCT04847297

Intervention type: PROCEDURE
Intervention: Preoperative drainage and pancreatoduodenectomy
Description: Preoperative biliary drainage before surgical removal of the tumor
Study: NCT06282016

Intervention type: OTHER
Intervention: Case-control study (no intervention)
Description: Observation of risk factors in cases and controls

Intervention type: OTHER
Intervention: Case-control study (no intervention)
Description: Observation of risk factors in cases and controls
Study: NCT04847297

Intervention type: PROCEDURE
Intervention: Pancreatoduodenectomy
Description: Pancreatic tumor resection without previous preoperative biliary drainage
Study: NCT05723497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elderberry juice
Description: Participants will consume elderberry juice 1-week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: Participants will consume placebo for 1-week.
Study: NCT05432193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Ga-68]-PNT6555
Description: \[Ga-68\]-PNT6555 IV administered as imaging agent for PET/CT
Study: NCT06205407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris
Description: Manufactured at Viatris

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
Description: Manufactured at Neolpharma.
Study: NCT05765890

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT05432193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Lu-177]-PNT6555
Description: Patients with FAP-avid disease as determined by the \[Ga-68\]-PNT6555 screening PET/CT will receive \[Lu-177\]-PNT6555 at a fixed dose level for up to 6 doses at an interval of 6 weeks between each dose.
Study: NCT06558825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Intervention to Promote PrEP Uptake
Description: Provision of PrEP information through 3 counseling sessions, prevention navigation, and nurse practitioner-prescribed PrEP in an addiction treatment setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment Condition
Description: Participants in trauma treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention